α-gal PANC1 vaccine

The α-gal PANC1 vaccine is an experimental whole-cell cancer immunotherapy designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). It is derived from the human pancreatic cancer cell line PANC1, which endogenously expresses the tumor-associated antigen Mucin 1 (MUC1). The vaccine is created by transfecting PANC1 cells with the mouse α1,3-galactosyltransferase (α1,3GT) gene, leading to the expression of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on the cell surface. This approach exploits the high levels of naturally occurring anti-Gal antibodies in humans. When the vaccine is administered, these antibodies bind to the α-gal epitopes, opsonizing the cells and significantly enhancing their uptake by antigen-presenting cells (APCs). This process promotes the cross-presentation of MUC1 and other tumor-associated antigens, thereby stimulating potent B-cell and T-cell immune responses against pancreatic cancer cells.

Other names

alpha-gal PANC1 vaccinealpha-gal PANC-1 vaccinealpha-gal modified PANC1 vaccine